Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 8:104:adv12623.
doi: 10.2340/actadv.v104.12623.

Matching-adjusted Indirect Comparison of Dermatology Life Quality Index 0/1 Response in Trials of Calcipotriol Plus Betamethasone Dipropionate Foam and Cream Formulations in Patients with Psoriasis

Ahmad Jalili  1 , Henrik Thoning  2 , Marie Y Jablonski Bernasconi  2 , Kim Papp  3
Affiliations

Matching-adjusted Indirect Comparison of Dermatology Life Quality Index 0/1 Response in Trials of Calcipotriol Plus Betamethasone Dipropionate Foam and Cream Formulations in Patients with Psoriasis

Ahmad Jalili et al. Acta Derm Venereol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

AJ has been a consultant and advisor and/or received speaking fees and/or grants and/or served as an investigator in clinical trials for the following companies: AbbVie, Almirall, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galderma, GSK, LEO Pharma, Janssen, MSD, Novartis, Sanofi and UCB. HT and MYJB are employees at LEO Pharma. KAP has received honoraria for advisory board, speaker, consultant services, scientific officer and/or steering committees from AbbVie, Akros, Amgen, Bausch Health/Valeant, Boehringer Ingelheim, Celgene, Celltrion, Coherus, Eli Lilly, Forbion, Galderma, Janssen, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Merck (MSD), Merck-Serono, Mitsubishi Pharma, Novartis, Pfizer, Reistone, Sanofi-Aventis/Genzyme, Sandoz, Takeda, UCB, vTv Therapeutics and Xencor; and has received research grants from AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, Avillion, Bausch Health/Valeant, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Coherus, Dermavant, Dermira, Dow Pharma, Eli Lilly, Evelo, Galapagos, Galderma, Genentech, Gilead, GSK, Incyte, Janssen, Kyowa Hakko Kirin, LEO Pharma, Medimmune, Merck (MSD), Merck- Serono, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda and UCB.

Figures

Fig. 1
Fig. 1
Forest plots of (A) the anchored matching-adjusted indirect comparison (MAIC) of Dermatology Life Quality Index (DLQI) 0/1 response for Cal/BD foam at Week 4 vs calcipotriol (Cal)/ betamethasone dipropionate (BD) cream at Week 8 with Cal/BD gel as a common comparator and (B) unanchored MAICs of DLQI 0/1 response for Cal/BD foam at Week 4 vs Cal/BD cream at Week 8. (A) Odds ratios presented for achieving DLQI 0/1 response in an anchored MAIC of PSO-ABLE randomized controlled trial (RCT) vs US and EU RCTs of Cal/BD cream. DLQI 0/1 response rates are for the comparators vs Cal/BD gel. (B) Odds ratios (ORs) presented for achieving DLQI 0/1 response in unanchored MAICs of the Cal/BD foam RCTs (PSO-ABLE, LEO90100-07, and LP0053-1001); the PSO-LONG open-label phase; and the pooled Cal/BD foam individual patient data (IPD), vs US and EU RCTs of Cal/BD cream. 95% CI: 95% confidence interval; Pooled: pooled Cal/BD foam treatment groups (PSO-ABLE RCT arm, LEO90100-07 RCT arm, LP0053-1001 RCT arm, PSO-LONG open-label phase).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Rudnicka L, Olszewska M, Goldust M, Waśkiel-Burnat A, Warszawik-Hendzel O, Dorożyński P, et al. . Efficacy and safety of different formulations of calcipotriol/betamethasone dipropionate in psoriasis: gel, foam, and ointment. J Clin Med 2021; 10: 5589. - PMC - PubMed
    1. Paul C, Stein Gold L, Cambazard F, Kalb RE, Lowson D, Bang B, Griffiths CEM. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol 2017; 31: 119–126. - PMC - PubMed
    1. Koo J, Tyring S, Werschler WP, Bruce S, Olesen M, Villumsen J, Bagel J. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – a randomized phase II study. J Dermatol Treat 2016; 27: 120–127. - PMC - PubMed
    1. Pinter A, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M. A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. J Eur Acad Dermatol Venereol 2022; 36: 228–236. - PubMed
    1. tein Gold L, Green LJ, Dhawan S, Vestbjerg B, Praestegaard M, Selmer J. A phase 3, randomized trial demonstrating the improved efficacy and patient acceptability of fixed dose calcipotriene and betamethasone dipropionate cream. J Drugs Dermatol 2021; 20: 420–425. - PubMed